Gilead plans $4.3 billion deal to advance liver portfolio
As part of its proposed acquisition, Gilead will add a…
As part of its proposed acquisition, Gilead will add a potential best-in-disease treatment for second-line primary biliary cholangitis (PBC) to its liver portfolio.